GH

Guardant Health's stock price saw a 156.6% increase from October 2025 to October 2026. In the past six months, robust Q2 2026 financial results, which surpassed analyst expectations for EPS and revenue and led to raised full-year guidance, contributed to a 15% stock gain. Expanded payer coverage for the Shield test by UnitedHealthcare and EviCore by Evernorth, covering approximately 94 million lives, and its inclusion in American Cancer Society guidelines, positively impacted the stock. The company also received key FDA approval for Guardant360 CDx and positive clinical study data validated the utility of the Guardant Reveal liquid biopsy test, specifically the COSMOS-MEL01 study for melanoma patients. Bullish analyst commentary and raised price targets further supported the stock. Additionally, European approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH™ in advanced ER-positive breast cancer was announced. Guardant Health is scheduled to release its Q3 2026 financial results on November 5, 2026.